BCL2 and diffuse large B-cell lymphoma: Despite the previously identified tumor‐related biological prognostic factors, such as cell of origin [16, 38], TP53 aberrations [10, 11], BCL2 and MYC translocations and coexpression phenotype [8, 9, 10], or tumor infiltrating CD4+ lymphocytes [14, 15], age and IPI have remained the main tools in clinical practice to stratify the patients with DLBCL into low‐ and high‐risk groups and different therapies.